Recently, a Category 1 anti-tumor innovative drug “TQ-B3101 Capsule” developed by the Group has been submitted to and accepted by the National Medical Products Administration of the PRC. The indication for this application is non-small cell lung cancer which is positive for ROS1.
TQ-B3101 Capsule is a tyrosine kinase ROS1/ALK/c-Met small molecule inhibitor self-developed by the Group. TQ-B3101 can selectively inhibit the in vitro proliferation of ROS1-positive, ALK-positve and c-Met tumor cells, inducing the cell cycle arrest in G1 phase and inducing cell apoptosis. This will ultimately exert effective anti-tumor effects and improve the survival prognosis of patients with non-small cell lung cancer. Current clinical data showed that TQ-B3101 is apparently effective in the treatment of non-small cell lung cancer both in the short term and long term, and it has low eye toxicity and a good safety profile.
TQ-B3101 Capsule is another Category 1 innovative drug recently applied for marketing by the Group after TQ-B3139. The Group has continuously achieved breakthroughs on the research and development of innovative drugs, and our new drug pipeline has gradually entered the harvesting period.